Benchmark Boosts Integer (NYSE:ITGR) Price Target to $130.00

Integer (NYSE:ITGR) had its target price boosted by research analysts at Benchmark from $105.00 to $130.00 in a research note issued to investors on Thursday, Benzinga reports. The firm presently has a “buy” rating on the medical equipment provider’s stock. Benchmark’s price target would indicate a potential upside of 10.95% from the company’s current price.

A number of other brokerages also recently commented on ITGR. CL King began coverage on shares of Integer in a research report on Thursday, March 14th. They issued a “buy” rating and a $137.00 price objective for the company. KeyCorp reduced their target price on shares of Integer from $125.00 to $123.00 and set an “overweight” rating for the company in a report on Friday, February 16th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, Integer currently has an average rating of “Hold” and a consensus target price of $109.67.

Integer Stock Up 1.8 %

Integer stock traded up $2.11 during mid-day trading on Thursday, reaching $117.17. The company’s stock had a trading volume of 36,735 shares, compared to its average volume of 280,944. The company has a market capitalization of $3.91 billion, a price-to-earnings ratio of 43.64, a price-to-earnings-growth ratio of 1.41 and a beta of 1.09. Integer has a 12 month low of $69.40 and a 12 month high of $118.15. The business’s 50 day simple moving average is $107.25 and its 200 day simple moving average is $94.25. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.71 and a current ratio of 2.80.

Integer (NYSE:ITGR) last announced its quarterly earnings data on Thursday, February 15th. The medical equipment provider reported $1.39 EPS for the quarter, beating analysts’ consensus estimates of $1.34 by $0.05. Integer had a net margin of 5.68% and a return on equity of 10.80%. The company had revenue of $413.15 million during the quarter, compared to the consensus estimate of $409.04 million. During the same quarter last year, the firm posted $1.11 EPS. The company’s quarterly revenue was up 10.9% on a year-over-year basis. As a group, research analysts anticipate that Integer will post 5.28 earnings per share for the current year.

Hedge Funds Weigh In On Integer

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Handelsbanken Fonder AB grew its holdings in shares of Integer by 1.7% during the 4th quarter. Handelsbanken Fonder AB now owns 5,837 shares of the medical equipment provider’s stock valued at $578,000 after purchasing an additional 100 shares during the last quarter. Cetera Advisor Networks LLC raised its stake in shares of Integer by 2.4% during the fourth quarter. Cetera Advisor Networks LLC now owns 4,611 shares of the medical equipment provider’s stock valued at $457,000 after acquiring an additional 106 shares during the last quarter. Cornercap Investment Counsel Inc. raised its stake in shares of Integer by 1.0% during the fourth quarter. Cornercap Investment Counsel Inc. now owns 12,014 shares of the medical equipment provider’s stock valued at $1,190,000 after acquiring an additional 121 shares during the last quarter. Arizona State Retirement System raised its stake in shares of Integer by 1.4% during the third quarter. Arizona State Retirement System now owns 9,474 shares of the medical equipment provider’s stock valued at $743,000 after acquiring an additional 131 shares during the last quarter. Finally, Quadrant Capital Group LLC raised its stake in shares of Integer by 10.2% during the fourth quarter. Quadrant Capital Group LLC now owns 1,427 shares of the medical equipment provider’s stock valued at $141,000 after acquiring an additional 132 shares during the last quarter. 99.29% of the stock is currently owned by institutional investors and hedge funds.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.